Paysign, Inc. (PAYS) Stock Analysis and Metrics

Paysign

NASDAQ: PAYS

$8.63 ▲ +0.10 (+1.23%)

At close: Jul 8, 2026 · 2:53 PM UTC

Financial Ratios

Market Cap472.24 Mn

P/E45.39

P/S50.02

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)6.14 Mn

Add ratio to table…

About

Paysign, Inc. is a vertically integrated provider of prepaid card products and processing services for corporate, consumer and government entities. The company also offers life science technology solutions for blood and plasma collection organizations under the Apherion brand. It operates a high availability payment solutions platform that enables end to end management of the prepaid card lifecycle, including card design, production, distribution, transaction processing and customer service. Its cards are issued through relationships with partner banks and carry network brands such as Visa, MasterCard and others.

Paysign generates revenue from fees associated with the prepaid card lifecycle, including cardholder fees, interchange income, card program management fees, transaction claims processing fees, breakage and settlement income. Additionally, the company earns licensing, hosting and consulting fees from its Apherion software solutions sold to blood and plasma centers. Revenue is recognized when performance obligations are satisfied, with breakage accrued over the estimated card life based on historical redemption patterns.

Paysign competes in the prepaid card and financial technology markets alongside other payment processors, fintech firms and specialized program managers. Its competitive advantage stems from a vertically integrated platform that combines proprietary technology, direct bank relationships and in house customer service. This integration allows the company to offer customized solutions across corporate incentives, patient affordability, plasma donor payments and demand deposit products while maintaining control over data security and compliance.

The company serves a diverse base that includes corporations seeking employee or customer incentive programs, pharmaceutical companies providing patient affordability assistance, plasma collection centers compensating donors, government agencies administering benefits and various consumer facing brands offering reloadable or gift cards. Paysign notes that it does not rely on any single major customer and manages hundreds of programs with millions of cardholders across its verticals.

Investment Thesis

▲ Bull case

The patient affordability business showed an 82% increase in revenue to $15,700,000 in the quarter driven by a 49% rise in claim volume and the launch of four new programs. This performance indicates that the platform is capturing both new client logos and deeper wallet share from existing pharmaceutical partners. Management noted that the pipeline for net program adds is on track to exceed the 55 additions achieved in 2025 with a balanced split between brand new clients and expansion within current accounts. The company stated that its existing systems have sufficient capacity to support this growth without requiring additional capital expenditure or major IT build out. This combination of strong top line momentum and scalable infrastructure suggests the market may be underestimating the durability of the affordability revenue stream.
Operating margin expanded to 23.8% representing an increase of over 1,000 basis points year over year and demonstrating that each dollar of incremental revenue is converting to operating income at a high rate. The company highlighted that roughly $9,400,000 of incremental revenue generated $4,200,000 of incremental operating income during the quarter. This level of conversion reflects the operating leverage inherent in the combined pharma and plasma businesses as fixed costs are spread over a larger revenue base. Management expects the mix to continue shifting toward higher margin pharma revenue which should further lift the gross profit margin toward the guided range of 60% to 62% for the full year. If this trend persists the market may be undervaluing the earnings power that can be unlocked as scale continues.
Plasma revenue grew 24.9% year over year to $11,700,000 with average monthly revenue per center rising to $6,670 from $6,520 and average loads per center increasing for the first time since the industry inventory correction that began in 2024. This uptick in loads per center suggests that the previous donor supply overhang is being absorbed and that remaining centers are operating more efficiently. Management noted that the closure of nineteen low performing centers was driven by the sale or shutdown of locations that generated less than $3,500 per month in revenue well below the corporate average. The company expects cardholders from these centers to migrate to nearby locations without financial impact. If the migration occurs smoothly the plasma business could see sequential growth throughout the year as donor activity normalizes after tax season.
During the International Plasma Protein Congress in Milan the company engaged with plasmapheresis device manufacturers across the United States Europe and Asia to discuss direct integration of its software with collection hardware. Direct integration eliminates manual steps reduces human error and streamlines implementation for centers adopting the platform. While the call focused primarily on domestic performance management did not emphasize the potential revenue upside from licensing or service fees tied to these device level partnerships. Successful integration in Europe and Asia could open a new high margin software as a service revenue stream that is not yet reflected in current guidance. This hidden catalyst represents a structural shift toward a broader fintech healthcare ecosystem beyond the traditional patient affordability and plasma compensation markets.
The press release announcing Paysign’s participation in the twentieth annual Barrington Research Virtual Spring Investment Conference indicates that CFO Jeff Baker will be holding one on one presentations throughout the day. Such investor facing events often lead to increased institutional awareness and can facilitate new shareholder base development which may support the stock price independent of immediate operational results. While the earnings call did not highlight this conference as a near term catalyst the management team’s willingness to engage with a broad investor audience suggests confidence in the company’s growth story. Additional meetings at the conference could also uncover strategic partnership opportunities with life sciences firms seeking innovative payment solutions. The market may be underestimating the potential for these interactions to translate into tangible business wins in the coming quarters.

The patient affordability business showed an 82% increase in revenue to $15,700,000 in the quarter driven by a 49% rise in claim volume and the launch of four new programs. This performance indicates that the platform is capturing both new client logos and deeper wallet share from existing pharmaceutical partners. Management noted that the pipeline for net program adds is on track to exceed the 55 additions achieved in 2025 with a balanced split between brand new clients and expansion within current accounts. The company stated that its existing systems have sufficient capacity to support this growth without requiring additional capital expenditure or major IT build out. This combination of strong top line momentum and scalable infrastructure suggests the market may be underestimating the durability of the affordability revenue stream.
Operating margin expanded to 23.8% representing an increase of over 1,000 basis points year over year and demonstrating that each dollar of incremental revenue is converting to operating income at a high rate. The company highlighted that roughly $9,400,000 of incremental revenue generated $4,200,000 of incremental operating income during the quarter. This level of conversion reflects the operating leverage inherent in the combined pharma and plasma businesses as fixed costs are spread over a larger revenue base. Management expects the mix to continue shifting toward higher margin pharma revenue which should further lift the gross profit margin toward the guided range of 60% to 62% for the full year. If this trend persists the market may be undervaluing the earnings power that can be unlocked as scale continues.
Plasma revenue grew 24.9% year over year to $11,700,000 with average monthly revenue per center rising to $6,670 from $6,520 and average loads per center increasing for the first time since the industry inventory correction that began in 2024. This uptick in loads per center suggests that the previous donor supply overhang is being absorbed and that remaining centers are operating more efficiently. Management noted that the closure of nineteen low performing centers was driven by the sale or shutdown of locations that generated less than $3,500 per month in revenue well below the corporate average. The company expects cardholders from these centers to migrate to nearby locations without financial impact. If the migration occurs smoothly the plasma business could see sequential growth throughout the year as donor activity normalizes after tax season.
During the International Plasma Protein Congress in Milan the company engaged with plasmapheresis device manufacturers across the United States Europe and Asia to discuss direct integration of its software with collection hardware. Direct integration eliminates manual steps reduces human error and streamlines implementation for centers adopting the platform. While the call focused primarily on domestic performance management did not emphasize the potential revenue upside from licensing or service fees tied to these device level partnerships. Successful integration in Europe and Asia could open a new high margin software as a service revenue stream that is not yet reflected in current guidance. This hidden catalyst represents a structural shift toward a broader fintech healthcare ecosystem beyond the traditional patient affordability and plasma compensation markets.
The press release announcing Paysign’s participation in the twentieth annual Barrington Research Virtual Spring Investment Conference indicates that CFO Jeff Baker will be holding one on one presentations throughout the day. Such investor facing events often lead to increased institutional awareness and can facilitate new shareholder base development which may support the stock price independent of immediate operational results. While the earnings call did not highlight this conference as a near term catalyst the management team’s willingness to engage with a broad investor audience suggests confidence in the company’s growth story. Additional meetings at the conference could also uncover strategic partnership opportunities with life sciences firms seeking innovative payment solutions. The market may be underestimating the potential for these interactions to translate into tangible business wins in the coming quarters.

▼ Bear case

The patient affordability segment depends heavily on a limited number of large pharmaceutical manufacturers for the bulk of its revenue and claim volume. Management did not disclose the concentration of revenue among top clients during the call leaving investors unaware of how much of the 82% growth is tied to a handful of partners. If any of these key clients were to renegotiate terms reduce program spending or shift to an internal solution the resulting loss could be material and swift. The company’s statement that its pipeline is balanced between new clients and existing account expansion does not mitigate the risk that a single large client departure could erase multiple quarters of growth. This concentration risk represents a material unspoken vulnerability that the market may be overlooking.
The value of Paysign’s patient affordability platform is closely linked to its ability to help manufacturers navigate copay maximizer and accumulator programs that affect how patient assistance is applied to deductibles and out of pocket costs. While management acknowledged that these payer strategies influence client and platform demand it did not discuss potential regulatory or legislative changes that could weaken or eliminate the economic benefit of such programs. Any shift in pharmacy benefit manager rules or state legislation that curtails manufacturer copay assistance would directly reduce the financial assistance volumes processed through the platform. The lack of a detailed discussion on this risk suggests the market may be ignoring a plausible headwind that could compress both revenue and margin going forward.
Management asserted that the closure of nineteen low performing plasma centers will have no financial impact because affected cardholders are expected to migrate to nearby locations that continue to use Paysign services. This assumption relies on donor behavior remaining stable and on the geographic proximity of alternative centers being sufficient to retain volume. If a significant portion of cardholders fail to transition due to inconvenience loyalty to the former center or lack of awareness the resulting decline in plasma transaction volumes could offset gains from higher loads per center. The company provided no data on historical migration rates from similar past closures leaving the assertion unverified. Investors should consider the possibility that the plasma revenue rebound may be weaker than modeled if donor migration frictions arise.
The fully diluted share count increased to 61,000,000 from 55,100,000 a year ago reflecting ongoing stock based compensation awards and potential dilution from future equity issuances. While the company reported strong adjusted EBITDA growth the effective tax rate rose to 27.2% from 20.5% year over year due to discrete items tied to the increase in share price. This higher tax rate reduces the net income conversion from pretax earnings and could persist if the stock price remains elevated. Combined with share count expansion the per share earnings growth may be less impressive than the headline operating metrics suggest. The market may be overestimating the sustainability of EPS expansion without factoring in these dilutive and tax related pressures.
Although the company highlighted discussions with plasmapheresis device manufacturers in Europe and Asia regarding direct integration of its software it did not provide any timeline revenue expectations or investment requirements associated with bringing these partnerships to commercial fruition. Building out international sales channels adapting to local regulatory environments and establishing support infrastructure could require substantial upfront spending that is not currently reflected in the full year guidance. If the anticipated SaaS revenue stream fails to materialize or arrives later than expected the company may need to reallocate funds from other growth initiatives potentially slowing domestic expansion. The lack of concrete details on this opportunity creates uncertainty that the market may be underpricing as a risk to future growth.

The patient affordability segment depends heavily on a limited number of large pharmaceutical manufacturers for the bulk of its revenue and claim volume. Management did not disclose the concentration of revenue among top clients during the call leaving investors unaware of how much of the 82% growth is tied to a handful of partners. If any of these key clients were to renegotiate terms reduce program spending or shift to an internal solution the resulting loss could be material and swift. The company’s statement that its pipeline is balanced between new clients and existing account expansion does not mitigate the risk that a single large client departure could erase multiple quarters of growth. This concentration risk represents a material unspoken vulnerability that the market may be overlooking.
The value of Paysign’s patient affordability platform is closely linked to its ability to help manufacturers navigate copay maximizer and accumulator programs that affect how patient assistance is applied to deductibles and out of pocket costs. While management acknowledged that these payer strategies influence client and platform demand it did not discuss potential regulatory or legislative changes that could weaken or eliminate the economic benefit of such programs. Any shift in pharmacy benefit manager rules or state legislation that curtails manufacturer copay assistance would directly reduce the financial assistance volumes processed through the platform. The lack of a detailed discussion on this risk suggests the market may be ignoring a plausible headwind that could compress both revenue and margin going forward.
Management asserted that the closure of nineteen low performing plasma centers will have no financial impact because affected cardholders are expected to migrate to nearby locations that continue to use Paysign services. This assumption relies on donor behavior remaining stable and on the geographic proximity of alternative centers being sufficient to retain volume. If a significant portion of cardholders fail to transition due to inconvenience loyalty to the former center or lack of awareness the resulting decline in plasma transaction volumes could offset gains from higher loads per center. The company provided no data on historical migration rates from similar past closures leaving the assertion unverified. Investors should consider the possibility that the plasma revenue rebound may be weaker than modeled if donor migration frictions arise.
The fully diluted share count increased to 61,000,000 from 55,100,000 a year ago reflecting ongoing stock based compensation awards and potential dilution from future equity issuances. While the company reported strong adjusted EBITDA growth the effective tax rate rose to 27.2% from 20.5% year over year due to discrete items tied to the increase in share price. This higher tax rate reduces the net income conversion from pretax earnings and could persist if the stock price remains elevated. Combined with share count expansion the per share earnings growth may be less impressive than the headline operating metrics suggest. The market may be overestimating the sustainability of EPS expansion without factoring in these dilutive and tax related pressures.
Although the company highlighted discussions with plasmapheresis device manufacturers in Europe and Asia regarding direct integration of its software it did not provide any timeline revenue expectations or investment requirements associated with bringing these partnerships to commercial fruition. Building out international sales channels adapting to local regulatory environments and establishing support infrastructure could require substantial upfront spending that is not currently reflected in the full year guidance. If the anticipated SaaS revenue stream fails to materialize or arrives later than expected the company may need to reallocate funds from other growth initiatives potentially slowing domestic expansion. The lack of concrete details on this opportunity creates uncertainty that the market may be underpricing as a risk to future growth.

Peer Comparison

Companies in the Software - Infrastructure

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MSFT	Microsoft Corp	2,853.66 Bn	22.79	8.97	40.26 Bn
2	ORCL	Oracle Corp	408.21 Bn	23.92	6.06	122.34 Bn
3	PLTR	Palantir Technologies Inc.	300.98 Bn	131.24	57.61	-
4	PANW	Palo Alto Networks Inc	247.84 Bn	193.34	25.05	-
5	CRWD	CrowdStrike Holdings, Inc.	193.63 Bn	-1,201.41	40.24	0.75 Bn
6	FTNT	Fortinet, Inc.	117.45 Bn	60.08	16.52	0.50 Bn
7	NET	Cloudflare, Inc.	86.88 Bn	-1,001.47	37.31	1.29 Bn
8	SNPS	Synopsys Inc	86.18 Bn	1,416.99	10.76	10.04 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password